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Chronic kidney disease induces left 
ventricular overexpression of the 
pro-hypertrophic microRNA-212
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Fanni Márványkövi1, Mónika G. Kovács1, petra Diószegi1, László Bodai  5, Nóra Zsindely5, 
Márton pipicz1, Kamilla Gömöri6, Krisztina Kiss6, péter Bencsik6, Gábor Cserni4, 
László G. puskás2, Imre Földesi3, thomas thum7, sándor Bátkai7 & tamás Csont1
Chronic kidney disease (CKD) is a public health problem that increases the risk of cardiovascular 
morbidity and mortality. Heart failure with preserved ejection fraction (HFpeF) characterized by left 
ventricular hypertrophy (LVH) and diastolic dysfunction is a common cardiovascular complication of 
CKD. MicroRNA-212 (miR-212) has been demonstrated previously to be a crucial regulator of pathologic 
LVH in pressure-overload-induced heart failure via regulating the forkhead box O3 (FOXO3)/calcineurin/
nuclear factor of activated T-cells (NFAT) pathway. Here we aimed to investigate whether miR-212 and 
its hypertrophy-associated targets including FOXO3, extracellular signal-regulated kinase 2 (ERK2), and 
AMp-activated protein kinase (AMpK) play a role in the development of HFpeF in CKD. CKD was induced 
by 5/6 nephrectomy in male Wistar rats. Echocardiography and histology revealed LVH, fibrosis, 
preserved systolic function, and diastolic dysfunction in the CKD group as compared to sham-operated 
animals eight and/or nine weeks later. Left ventricular miR-212 was significantly overexpressed in 
CKD. However, expressions of FOXO3, AMPK, and ERK2 failed to change significantly at the mRNA 
or protein level. The protein kinase B (AKT)/FOXO3 and AKT/mammalian target of rapamycin (mTOR) 
pathways are also proposed regulators of LVH induced by pressure-overload. Interestingly, phospho-
AKT/total-AKT ratio was increased in CKD without significantly affecting phosphorylation of FOXO3 or 
mTOR. In summary, cardiac overexpression of miR-212 in CKD failed to affect its previously implicated 
hypertrophy-associated downstream targets. thus, the molecular mechanism of the development 
of LVH in CKD seems to be independent of the FOXO3, ERK1/2, AMPK, and AKT/mTOR-mediated 
pathways indicating unique features in this form of LVH.
Chronic kidney disease (CKD) is a clinical syndrome defined as persistent deterioration of kidney function or 
alteration in kidney structure or both affecting the health of the individual1–3. The prevalence of CKD varies 
between 7–12% in the world1–3. The presence of CKD is an independent risk factor for cardiovascular com-
plications3,4. Indeed, cardiovascular diseases are the leading cause of morbidity and mortality in all stages of 
CKD3,4. Cardiovascular events are more commonly fatal in patients with CKD than in individuals without CKD5. 
Cardiovascular disease in CKD often presents as HFpEF characterized by left ventricular hypertrophy (LVH) and 
diastolic dysfunction1,6. Later, LVH could contribute to the development of heart failure with reduced ejection 
fraction, arrhythmias, ischemic heart disease, and sudden cardiac death in CKD1,6. LVH is present in 50–70% 
of CKD patients and up to 90% in dialyzed patients with end-stage renal disease1,7–10. Although traditional risk 
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factors, such as hypertension and diabetes mellitus, contribute to high rates of LVH in CKD, the regression of 
LVH after kidney transplantation suggests other CKD-specific risk factors that remain poorly characterized 
yet1,11,12. Both pre-clinical and clinical studies proved that factors related to CKD itself provoke the development 
of LVH, regardless of pressure- and volume-overload13–17. Therefore, the discovery of specific, so far unexplored 
mechanisms in the development of LVH is needed to identify novel therapeutic targets for reducing the burden 
of cardiovascular disease in CKD.
Endogenous microRNAs (miR) are short (approximately 22 bp), non-coding RNA species that are 
post-transcriptional regulators targeting specific mRNAs, resulting in the suppression of protein synthesis or the 
increase of mRNA degradation via complementary binding, thus influencing cellular function18. miRs have been 
described as “master switches” in cardiovascular biology19–22. The dysregulation of specific miRs has been impli-
cated as key pathological factors in many cardiovascular diseases19–22. The miR-212/132 cluster was identified as 
a central regulator of the development of pressure-overload-induced LVH and heart failure via the repression of 
the anti-hypertrophic transcription factor FOXO323. Moreover, the overexpression of miR-212 separately from 
miR-132 was reported to play a role in the development of LVH and heart failure via fetal gene reprogramming 
in human hearts24. Furthermore, the pro-hypertrophic potential of miR-212 was also confirmed in primary neo-
natal rat cardiomyocytes25. Beyond FOXO3, other LVH-associated predicted or validated targets of miR-212 
were also identified. These include for instance the extracellular signal-regulated kinase 2 (ERK2)26, myocyte 
enhancer factor 2a (MEF2A)27; AMP-activated protein kinase, (AMPK)28; heat shock protein 40 (HSP40)29; sir-
tuin 1, (SIRT1)30; and phosphatase and tensin homolog (PTEN)31, etc.
So far there is no literature data available on the cardiac expression of miR-212 and its targets in CKD. 
Therefore, we aimed to investigate the potential role of miR-212 and its hypertrophy-associated targets in LVH 
in CKD.
Results
The development of CKD in 5/6 nephrectomized rats. During the follow-up period, the survival rate 
was 100% among sham-operated animals and 85% among 5/6 nephrectomized animals. Concentrations of serum 
and urine metabolites were measured at week −1, 4 and at the endpoint (week 8 in case of urine parameters and 
week 9 in case of serum parameters) to verify the development of CKD induced by 5/6 nephrectomy (Figs 1 and 2). 
The serum carbamide and creatinine levels were significantly increased at week 4 and the endpoint in the 5/6 
nephrectomized rats as compared to the baseline values or the values of the sham-operated animals at each time 
point representing continously worsening renal function and the development of CKD (Fig. 2a,b). Likewise, in 
the 5/6 nephrectomized rats, urine protein concentration was significantly increased showing impaired glomer-
ular function at the endpoint (Fig. 2c). Accordingly, creatinine clearance was significantly decreased in the 5/6 
nephrectomized rats both at week 4 and at the endpoint as compared to the sham-operated rats showing the 
development of CKD (Fig. 2d). By contrast, creatinine clearance was significantly increased in the sham animals 
at the endpoint as compared to the baseline values due to normal growth of healthy animals (Fig. 2d). Serum 
potassium and magnesium ions were significantly increased at week 9 in the CKD group as compared to the sham 
group showing disturbed electrolyte homeostasis (Table 1). Glucose intolerance and insulin resistance are com-
mon complications in CKD and elevated insulin level could have a hypertrophic effect on the heart. Interestingly, 
there was no significant difference in blood glucose levels between the two groups at any time point of the oral 
glucose tolerance test (OGTT) at week 8 excluding glucose intolerance in the CKD group (Table 1). However, 
Figure 1. Experimental protocol. BP: blood pressure, CF: coronary flow, CKD: chronic kidney disease, OGTT: 
oral glucose tolerance test, Op: operation.
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plasma insulin concentration was significantly lower in the CKD animals at week 8 as compared to sham-oper-
ated animals suggesting diminished function of the pancreatic beta cells (Fig. 1 and Table 1).
the development of HFpeF in CKD. Transthoracic echocardiography was performed at week −1, 4 and 
8 to investigate whether the development of CKD leads to an alteration in myocardial morphology and function 
(Figs 1, 3 and Table 2). At week −1, there was no difference in any measured parameters between the two groups 
(Fig. 3 and Table 2). At week 4, the diastolic function-associated e′ was significantly decreased as compared to 
the sham group (Table 2), and the anterior and septal diastolic wall thicknesses were significantly increased in 
the CKD group as compared to the sham group or baseline values showing starting LVH with mild diastolic 
Figure 2. The development of chronic kidney disease. (a) Serum carbamide level, (b) serum creatinine level, (c) 
urine protein level (numeric p-value over the bars refers to a comparison between groups within the same time 
point), (d) creatinine clearance was calculated from urine volume, urine and serum creatinine concentrations 
according to a formula (urine creatinine concentration [μM] × urine volume for 24 h [mL])/(serum creatinine 
concentration [μM] × 24 × 60 min). ¥Urine volume and urine creatinine concentration were measured at week 8 
and serum creatinine concentration was determined at week 9. White bars represent the sham-operated group 
and grey bars represent the chronic kidney disease (CKD) group. Values are means ± SEM, n = 9–10, *p < 0.05 
vs. sham within the same time point, #p < 0.05 vs. week −1.
Parameter (unit)
endpoint
Sham CKD p-value
Serum sodium ion (mmol/L) 144 ± 1 144 ± 1 0.786
Serum potassium ion (mmol/L) 5.50 ± 0.26 6.46 ± 0.34* 0.039
Serum chloride ion (mmol/L) 104 ± 1 102 ± 1 0.083
Serum calcium ion (mmol/L) 2.61 ± 0.02 2.66 ± 0.11 0.556
Serum magnesium ion (mmol/L) 0.95 ± 0.02 1.30 ± 0.14* 0.012
Serum phosphate ion (mmol/L) 2.55 ± 0.06 3.21 ± 0.45 0.117
Blood glucose 0′ min (mmol/L) 5.55 ± 0.13 5.48 ± 0.16 0.719
Blood glucose 30′ min (mmol/L) 7.24 ± 0.35 7.85 ± 0.34 0.235
Blood glucose 60′ min (mmol/L) 7.36 ± 0.24 7.96 ± 0.23 0.088
Blood glucose 90′ min (mmol/L) 5.71 ± 0.12 5.86 ± 0.17 0.519
Plasma insulin/plasma protein (ug/g) 0.032 ± 0.001 0.012 ± 0.002* 0.009
Table 1. Serum and plasma parameters in the CKD model. Values are mean ± SEM, n = 9–10, *p < 0.05 vs. 
control, unpaired t-test. CKD: chronic kidney disease.
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dysfunction (Fig. 3). At week 8, left ventricular wall thicknesses including anterior and septal walls both in systole 
and diastole were significantly increased in CKD rats as compared to the sham group and the baseline values 
pointing to the presence of LVH (Fig. 3a–e). The inferior and posterior wall thicknesses in diastole showed a 
tendency of increase in the CKD group as compared to the sham group at week 8 (Table 2). Both end-systolic 
and end-diastolic diameters were significantly increased in both groups as compared to baseline values at week 4 
and 8 due to the growth of the animals (Table 2). Left ventricular end-systolic, end-diastolic, and stroke volumes 
were also decreased in the CKD group as compared to the sham group at week 8 (Table 2). Ejection fraction 
remained unchanged in the CKD rats compared to the sham rats or the baseline values both at week 4 and 8 
showing a characteristic picture of the entity called HFpEF (Fig. 3g). There was no significant difference in heart 
rate between the two groups at any time point (Fig. 3f). Cardiac output was significantly reduced in the CKD rats 
as compared to the sham group at week 8 (Table 2). More importantly, the ratio of the early flow velocity E and 
the septal mitral annulus velocity e′ significantly increased in CKD rats at week 8 indicating diastolic dysfunction 
(Fig. 3h). Another parameter of the diastolic function, the isovolumic relaxation time was significantly longer 
in the CKD animals as compared to controls at week 8 pointing to abnormal myocardial relaxation (Table 2). 
Systolic parameters including isovolumic contraction time and ejection time and the myocardial performance 
index (Tei index) remained unchanged in the CKD group as compared to the sham group at any time point 
(Table 2). Hypertension is a well-known complication in CKD and also an independent risk factor for the devel-
opment of LVH. Interestingly, there was only a tendency of a slight increase in blood pressure in the CKD group 
as compared to the sham-operated group at week 8 (Table 3).
At week 9, at autopsy, heart weight and heart weight to body weight ratio were significantly increased in CKD 
animals than in controls indicating macroscopic signs of hypertrophy (Table 3). Moreover, basal coronary flow – 
measured in isolated perfused hearts - was significantly reduced in the CKD group as compared to the sham 
group (13 ± 0.5 vs. 18 ± 1.5 mL/min) supporting the reduced cardiac output assessed by echocardiography in 
vivo (Table 2). At autopsy, the weight of the whole left kidney in the sham-operated group was smaller than the 
remaining one-third of the left kidney in the CKD group (1145 ± 75 vs. 2053 ± 118 mg) suggesting marked renal 
hypertrophy in the CKD animals.
Cardiomyocyte hypertrophy and interstitial fibrosis in CKD. Cardiomyocyte diameters were meas-
ured histologically to verify the development of LVH seen on echocardiographic images and at autopsy (Fig. 4a,b). 
Figure 3. Echocardiographic results. (a) Representative M-mode images, (b) anterior wall thicknesses in 
systole (AWTs), (c) anterior wall thicknesses in diastole (AWTd), (d) septal wall thicknesses in systole (SWTs), 
(e) septal wall thicknesses in diastole (SWTd), (f) heart rate, (g) ejection fraction, (h) E/e′ ratio. White bars 
represent the sham-operated group, and grey bars represent the chronic kidney disease (CKD) group. Values 
are means ± SEM, n = 9–10, *p < 0.05 vs. sham within the same time point, #p < 0.05 vs. week -1. (Numeric 
p-values over the bars refer to the comparison between groups within the same time point)
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Cross-sectional cardiomyocyte diameters were significantly increased in the CKD group as compared to the sham 
group proving the presence of LVH at the cellular level (Fig. 4a,b).
Collagen deposition was assessed to investigate the development of fibrosis in CKD (Figs. 4c–f). Significant 
interstitial fibrosis was found with consistent interstitial collagen depositions in all studied segments of the CKD 
hearts (Fig. 4c–f). Matrix metalloprotease 2 (MMP-2) can break down collagen in the extracellular matrix. Its 
cardiac activity showed a tendency of increase in CKD as compared to the sham group (Fig. 4g) suggesting that 
the balance between collagen breakdown and deposition might have been shifted towards deposition.
Molecular markers of LVH and heart failure in CKD. The expression of LVH- and heart failure-associated 
markers were measured by qRT-PCR. Among hypertrophy markers, left ventricular expression of alpha-MHC (Myh6) 
was significantly decreased in CKD as compared to controls (Table 4). However, left ventricular mRNA level of 
beta-MHC (Myh7) did not change in CKD as compared to the sham group (Table 4). The increase in the beta-MHC 
to alpha-MHC ratio is a characteristic change in LVH. The left ventricular expression of the pro-hypertrophic myocyte 
enhancer factor 2 C (Mef2c) and myocyte enhancer factor 2D (Mef2d) did not increase in the CKD group as compared 
to the sham group (Table 4).
Among heart failure markers, the mRNA level of the A-type natriuretic peptide (ANP, [Nppa]) significantly 
increased in CKD as compared to the sham group, while the mRNA level of the B-type natriuretic peptide (BNP, 
[Nppb]) did not change significantly (Table 4).
Left ventricular overexpression of miR-212 in CKD. Left ventricular expression of miR-212 signifi-
cantly increased in CKD as compared to the sham group (Fig. 5a).
Parameter (unit) View/Mode
week −1 week 4 week 8
Sham CKD p-value Sham CKD p-value Sham CKD p-value
LV 
MORPHOLOGY
Inferior wall thickness-
systolic (mm)
short axis/
MM 3.24 ± 0.14 3.12 ± 0.11 0.553 2.97 ± 0.19 3.18 ± 0.17 0.416 3.16 ± 0.16 3.41 ± 0.24 0.381
Inferior wall thickness-
diastolic (mm)
short axis/
MM 2.00 ± 0.23 1.59 ± 0.07 0.132 1.83 ± 0.12 2.01 ± 0.14 0.325 1.87 ± 0.12 2.39 ± 0.26
# 0.081
Posterior wall 
thickness-systolic (mm)
long axis/
MM 3.51 ± 0.14 3.33 ± 0.16 0.394 3.07 ± 0.14 3.48 ± 0.20 0.107 3.13 ± 0.16 3.44 ± 0.27 0.305
Posterior wall 
thickness-diastolic 
(mm)
long axis/
MM 1.97 ± 0.10 1.91 ± 0.15 0.773 1.75 ± 0.11 2.23 ± 0.22 0.057 1.76 ± 0.10 2.27 ± 0.29 0.099
Left ventricular end 
diastolic diameter 
(mm)
long axis/
MM 4.81 ± 0.21 4.68 ± 0.28 0.699 6.25 ± 0.24
# 5.88 ± 0.38# 0.400 6.58 ± 0.25# 6.40 ± 0.43# 0.715
Left ventricular end 
diastolic diameter 
(mm)
short axis/
MM 4.55 ± 0.37 5.12 ± 0.27 0.243 6.02 ± 0.15
# 6.22 ± 0.33# 0.562 6.40 ± 0.26# 6.22 ± 0.40# 0.712
Left ventricular end 
systolic diameter (mm)
long axis/
MM 1.44 ± 0.18 1.89 ± 0.29 0.190 2.59 ± 0.27
# 2.48 ± 0.26 0.779 3.32 ± 0.25# 2.97 ± 0.39# 0.453
Left ventricular end 
systolic diameter (mm)
short axis/
MM 1.85 ± 0.45 1.44 ± 0.26 0.462 2.89 ± 0.23
# 2.79 ± 0.33# 0.790 3.03 ± 0.21# 3.17 ± 0.44# 0.769
LV FUNCTION
Fractional shortening 
(%)
long axis/
MM 70 ± 3 66 ± 3 0.297 59 ± 4
# 58 ± 4# 0.797 50 ± 2# 55 ± 4# 0.247
Fractional shortening 
(%)
short axis/
MM 71 ± 3 73 ± 3 0.683 56 ± 3
# 57 ± 4# 0.860 53 ± 2# 51 ± 5# 0.745
Left ventricular end-
diastolic volume (µl) 4CH/2D 71 ± 10 74 ± 12 0.826 87 ± 12 122 ± 20
# 0.145 136 ± 20# 78 ± 7* 0.014
Left ventricular end-
systolic volume (µl) 4CH/2D 27 ± 4 27 ± 3 0.960 34 ± 6 52 ± 12
# 0.198 55 ± 12# 27 ± 3 0.054
Stroke volume (µl) 4CH/2D 45 ± 6 47 ± 7 0.756 53 ± 6 70 ± 9 0.141 82 ± 8# 51 ± 5* 0.004
Cardiac output (mL/
min) 4CH/2D 18 ± 3 19 ± 3 0.932 21 ± 2 26 ± 4 0.225 29 ± 2
# 17 ± 2* 0.001
E-wave (m/s) 4CH/PWD 0.84 ± 0.07 0.84 ± 0.06 0.961 0.99 ± 0.08 0.88 ± 0.07 0.317 0.71 ± 0.03 0.73 ± 0.06 0.718
e′-wave (m/s) 4CH/TD 0.065 ± 0.003
0.059 ± 
0.003 0.217
0.079 ±  
0.003
0.063 ±  
0.008* 0.027
0.066 ±  
0.005
0.049 ±  
0.005* 0.014
Isovolumic contraction 
time (ms) 4CH/PWD
17.17 ± 
1.38 18.26 ± 1.92 0.644 14.37 ± 1.10 16.85 ± 0.56 0.069 17.53 ± 1.19 20.19 ± 1.80 0.227
Isovolumic relaxation 
time (ms) 4CH/PWD 27.20 ± 2.72 26.37 ± 3.04 0.840 22.83 ± 2.01 26.52 ± 2.32 0.244 25.50 ± 1.71 32.33 ± 2.68* 0.042
Ejection time (ms) 4CH/PWD 50.60 ± 2.17 45.22 ± 4.29 0.264 54.17 ± 2.37 61.00 ± 5.88# 0.278 62.13 ± 2.10 66.15 ± 3.54# 0.331
Tei index 4CH/PWD 0.90 ± 0.09 1.01 ± 0.08 0.264 0.71 ± 0.07 0.76 ± 0.07 0.574 0.71 ± 0.06 0.75 ± 0.06 0.665
Table 2. Effects of CKD on various in vivo left ventricular morphological and functional parameters measured 
by transthoracic echocardiography. Transthoracic echocardiographic measurements were performed −1, 4, and 8 
weeks after 5/6 nephrectomy. Values are mean ± SEM, n = 9–10, *p < 0.05 vs. control, unpaired t-test within each 
time point. p-values refer to the unpaired t-test at each time point. #p < 0.05 vs. week −1, repeated measures two-way 
ANOVA (Holm-Sidak post hoc test). 2D, two dimensional, 4CH: four chambers view, CKD: chronic kidney disease; 
E-wave, early ventricular filling velocity; MM, M (motion) Mode; PWD, pulse wave Doppler; TD, tissue Doppler.
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No change in left ventricular FOXO3 expression and phosphorylation in CKD. We measured the 
left ventricular expression of FOXO3 which is a validated target of miR-21223,32. Left ventricular FOXO3 level 
failed to decrease at the mRNA and the protein level in the CKD group as compared to the sham group (Fig. 5e–
f). In pressure-overload-induced LVH, increased phospho-FOXO3/total FOXO3 ratio is a characteristic shift. 
However, in our current study, the left ventricular phospho-FOXO3 level and the phospho-FOXO3/total FOXO3 
ratio was not increased in CKD as compared to the sham group (Fig. 5g–h).
Increased left ventricular phospho-AKT/total AKT ratio in CKD. Phospho-AKT has been 
reported to play a role in the development of LVH both in a FOXO3-dependent or -independent manner in 
non-CKD-induced forms of LVH32–34. In our present study, left ventricular expression of total AKT did not differ 
between the two groups at the protein level (Fig. 5b). However, the expression of the phospho-AKT showed an 
increasing tendency in CKD hearts as compared to controls (Fig. 5c). The phospho-AKT/total AKT ratio signifi-
cantly increased in CKD as compared to the sham group (Fig. 5d).
No change in left ventricular mtoR expression and phosphorylation in CKD. The AKT/mTOR 
pathway has been suggested to be another crucial regulator of pressure-overload-induced LVH33. Therefore, the 
left ventricular expression of mTOR and phosho-mTOR were also measured at the protein level in our present 
study. The expression of both mTOR and phospho-mTOR failed to change significantly at the protein level in 
the CKD group as compared to the control group (Fig. 6a,b). Accordingly, phospho-mTOR/mTOR ratio did not 
change significantly in response to CKD (Fig. 6c).
Molecular markers of the pro-hypertrophic calcineurin/NFAT pathway. Beyond other molecu-
lar pathways, FOXO3 protein regulates the pro-hypertrophic calcineurin/NFAT pathway35. This pathway was 
shown to be regulated by miR-212 via FOXO3 in LVH induced by pressure-overload23. In our present study, left 
ventricular expression of the marker molecules of the calcineurin/NFAT pathway was measured by qRT-PCR. 
The expression of protein phosphatase 3, catalytic subunit alpha and beta (i.e., calcineurin A-alpha, [Ppp3ca] 
and calcineurin A-beta, [Ppp3cb]), myocyte-enriched calcineurin-interacting protein 1 (MCIP1.4, [Rcan1]), 
and the calcineurin-dependent cytoplasmic nuclear factor of activated T-cells (Nfatc4) did not change in CKD 
as compared to the sham group (Table 5). In contrast, the atrophic gene atrogin-1 (Fbx32) was significantly 
down-regulated in CKD as compared to the sham group (Table 5).
Hypertrophy-associated targets of miR-212 beyond FOXO3: no change in left ventricular 
ERK1/2 and AMPK expression and phosphorylation in CKD. Beyond FOXO3, several 
hypertrophy-associated predicted targets of miR-212 were also measured in the current study. We have inves-
tigated the left ventricular expression of the extracellular signal-regulated kinase 2 (ERK2, [Mapk1]), the myo-
cyte enhancer factor 2a (Mef2a); the protein kinase AMP-activated catalytic subunit alpha 2 (AMPK, [Prkaa2]); 
DnaJ heat shock protein family member A2 (HSP40, [Dnaja2]); sirtuin 1, transcript variant X1 (Sirt1); and 
phosphatase and tensin homolog (Pten) at the transcript level (Table 6). These target mRNAs failed to show 
significant down-regulation in response to CKD as compared to control hearts (Table 6). We selected ERK2 
(measured together with ERK1) and AMPK to determine their cardiac expression also at the protein level (Fig. 7). 
In our current study, left ventricular total ERK1 and ERK2 levels, phospho-ERK1 and phospho-ERK2 levels, 
phospho-ERK1/total ERK1 ratio, phospho-ERK2/total ERK2 ratio, total AMPK level, phospho-AMPK level, and 
phospho-AMPK/total AMPK ratio failed to change significantly in CKD as compared to the sham group (Fig. 7). 
Therefore, these targets of miR-212 do not seem to play a crucial role in the development of LVH in CKD.
Discussion
5/6 nephrectomy is probably the most established model of progressive renal failure with loss of renal mass36. 5/6 
nephrectomy mimics the consequences of the reduction of functional nephron number36. In this model of CKD, 
cardiac hypertrophy, interstitial fibrosis, and diastolic dysfunction are consistent characteristics; however, severe 
hypertension is not usually a feature of this model36–39. In our current study, the development of CKD, and sig-
nificant cardiac morphological and functional changes were confirmed 8 and/or 9 weeks after 5/6 nephrectomy. 
Animals presented LVH and diastolic dysfunction which are the hallmarks of HFpEF. Cardiac interstitial fibrosis 
was also present in our CKD model. Since interstitial fibrosis is a final major endpoint of cardiac pathologies in 
Parameters Sham CKD p-value
Body weight (g) (week −1) 283 ± 6 284 ± 12 0.954
Body weight (g) (week 9) 431 ± 13 425 ± 13 0.734
Heart weight (mg) 1193 ± 41 1318 ± 55* 0.031
Heart weight/body weight (mg/g) 2.77 ± 0.06 3.11 ± 0.13* 0.029
Systolic blood pressure (mmHg) 138 ± 3 146 ± 5 0.145
Diastolic blood pressure (mmHg) 117 ± 2 122 ± 4 0.240
Mean arterial blood pressure (mmHg) 127 ± 2 134 ± 4 0.148
Table 3. The effect of CKD on blood pressure, body weight and heart weight. Values are mean ± SEM, n = 9–10, 
*p < 0.05 vs. control, unpaired t-test. CKD: chronic kidney disease. Blood pressure was measured at week 8 in a 
subgroup of animals. Heart weight was measured at week 9.
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CKD, our model also seems to be an adequate one in a series of future investigations with different anti-fibrotic 
agents. In our present model, interstitial fibrosis and cardiomyocyte hypertrophy might lead to increased car-
diac stiffness and diastolic dysfunction without hypertension. The lack of severe hypertension, atherosclerosis 
and glucose intolerance makes it possible to study the direct effects and mechanisms of CKD on left ventricular 
hypertrophy and fibrosis. While traditional cardiovascular risk factors such as hypertension, atherosclerosis, and 
diabetes mellitus, are highly prevalent in CKD patients, results of clinical trials focusing on controlling such 
factors have been largely disappointing36. Both pre-clinical and clinical studies proved that factors related to 
CKD itself provoke the development of LVH and fibrosis, regardless of pressure- and volume-overload13–17. The 
CKD-specific risk factors can contribute to the development of cardiac hypertrophy and remodeling. These fac-
tors may include (i) uremic toxins (such as indoxyl sulfate) inducing pro-fibrotic and oxidative pathways36–40, (ii) 
renal anemia due to erythropoietin deficiency36,41, (iii) neurohormonal disturbances including the activation of 
the renin-angiotensin-aldosterone system and sympathetic nervous system with decreased nitric-oxide levels36,42, 
(iv) secondary hyperparathyroidism with hyperphosphatemia36,43, (v) fibroblast growth factor 23 (FGF23), pri-
marily involved in CKD-induced mineral and bone disorder36,44, (vi) insulin resistance and glucose intolerance 
leading to cardiometabolic complications36,45, etc.
MiRs have been shown to be crucial contributors to cardiovascular biology and disease development19–24,46. So 
far, only a few studies have been published describing the role of miRs in the development of LVH and fibrosis in 
CKD. Chuppa et al. published recently that the suppression of miR-21 protected rats with 5/6 nephrectomy from 
developing LVH and improved left ventricular function via PPAR-alpha-mediated pathways47. It has also been 
reported that activated Na+/K+-ATPase signaling could repress the cardiac expression of miR-29b which lead to 
increased collagen synthesis in CKD48. Moreover, repression of miR-29b and miR-30c played a role in the devel-
opment of cardiac fibrosis in CKD via targeting the pro-fibrotic molecules collagen-1a1, matrix metalloproteinase 
2 and connective tissue growth factor49. Cardiac repression of miR-208 and overexpressed circulating miR-133a 
were also associated with cardiac hypertrophy in CKD50,51. However, there is no literature data on the cardiac 
expression of the pro-hypertrophic miR-212 in CKD so far. It has been previously demonstrated that miR-212 
Figure 4. Histology and zymography results at week 9. (a) Hematoxylin-eosin stained slides, black scale 
bars represent 50 µm and 20 µm at 40X and 100X magnification, respectively, (b) Cardiomyocyte diameter, 
(c) Picrosirius red and fast green stained slides, black scale bars represent 50 µm and 20 µm at 20X and 40X 
magnification, respectively, (d) Anterior wall (AW) collagen content, (e) Septal collagen content (f) Left 
ventricular (LV) collagen content, (g) MMP-2 activity. White bars represent the sham-operated group, and grey 
bars represent the chronic kidney disease (CKD) group. Values are means ± SEM, n = 8–9, *p < 0.05, unpaired 
t-test.
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is overexpressed in human heart failure24 and transverse aortic constriction-induced LVH and heart failure in 
mice23. MiR-212 has been shown to be a key regulator in the development of LVH and heart failure via the repres-
sion of the anti-hypertrophic transcription factor FOXO3 and the overactivation of the calcineurin/NFAT sign-
aling during heart failure development23. In our present study, LVH and HFpEF in CKD were accompanied by 
the overexpression of miR-212. By contrast, the cardiac expression of FOXO3 failed to decrease at the mRNA and 
the protein level in CKD. Moreover, the phospho-FOXO3/total FOXO3 ratio did not change in CKD. Therefore, 
our results suggest that FOXO3 might not play a substantial role in the development of LVH and fibrosis in CKD.
The protein kinase AKT was also reported to be a crucial regulator of LVH induced by pressure-overload32–34. 
AKT could be regulated via both FOXO3-dependent and independent pathways33–35. Therefore, we measured the 
protein level of both total AKT and phospho-AKT. In our present study, the phospho-AKT/total AKT ratio sig-
nificantly increased which is a characteristic shift in pressure-overload-induced cardiac hypertrophy52. Moreover, 
the AKT/mTOR pathway plays a crucial role in the development of left ventricular hypertrophy33,53. Therefore, 
the expression of mTOR and phospho-mTOR proteins were measured and no difference was found between the 
sham-operated and CKD group in our present study. In contrast, a preclinical study reported that 12 months long 
treatment with the mTOR inhibitor rapamycin resulted in the normalization of heart weight and cardiac mTOR 
signaling pathway in Han:SPRD rats with polycystic kidney disease54. In our present study, we used a model in 
the early stages of CKD with preserved systolic function. The different duration and severity of our CKD model 
as compared to the aforementioned Han:SPRD rats54 might explain the different mTOR expression in our present 
study.
The hypertrophic calcineurin/NFAT pathway could also be activated via FOXO3-dependent and independent 
mechanisms52,55. NFAT proteins are dephosphorylated by the Ca2+∕calmodulin-dependent phosphatase calcineu-
rin and translocated to the nucleus to activate target gene expression56. In our present study, cardiac mRNA levels 
of calcineurin A-alpha, calcineurin A-beta, and NFAT did not change in the CKD hearts as compared to controls 
suggesting that calcineurin and NFAT are not overexpressed in LVH in CKD. Moreover, overexpressed FOXO3 
was reported to increase the expression of the atrophic gene atrogin-1 at the mRNA level, and atrogin-1 could 
directly reduce the activity of calcineurin-A57. In our present study, FOXO3 failed to change, and atrogin-1 was 
significantly repressed at the mRNA level in CKD. The cardiac expression of atrogin-1 might be regulated by 
FOXO3-independent mechanisms in CKD (e.g., miRs beyond miR-212).
To find potential FOXO3-independent pro-hypertrophic mechanisms in CKD, we also investigated the 
expression of several other regulatory molecules that are predicted targets of miR-212 and associated with LVH. 
Target mRNAs were myocyte enhancer factor 2a (Mef2a); AMP-activated protein kinase (AMPK, [Prkaa2]); 
heat shock protein 40 (HSP40, [Dnaja2]); sirtuin 1 (Sirt1); phosphatase and tensin homolog (Pten), extracellular 
signal-regulated kinase 2 (ERK2, [Mapk1]). These target mRNAs failed to show significant repression in the car-
diac tissue samples of CKD animals as compared to control hearts. We further investigated the cardiac expression 
of ERK1, ERK2 and AMPK at the protein level in our present study. In our hands, no significant change was 
found in the cardiac expression and phosphorylation of ERK1, ERK2 and AMPK in CKD as compared to the 
sham-operated animals. Literature data are controversial on the cardiac activity of ERK1/2 pathway in CKD. 
Liu et al. showed increased cardiac phospho-ERK/total ERK ratio in male Sprague Dawley rats 8 weeks after 5/6 
nephrectomy58. In contrast, Hernandez-Resendiz et al. found decreased phospho-ERK/total ERK ratio in male 
Wistar rats 4 weeks after 5/6 nephrectomy59. Haq et al. reported that ERK1/2 and phosphoinositide 3-kinase/ pro-
tein kinase B/glycogen synthase kinase-3β (PI3K/AKT/GSK-3β) cascades are not the predominant pathways in 
human hearts with compensated LVH60. However, this pattern is reverted in failing hearts60. Therefore, a plausible 
explanation for our findings may be that our CKD model represents the compensated phase of LVH. Interestingly, 
AMPK was implicated as a central regulator of the development of LVH induced by pressure-overload either 
directly or indirectly via numerous downstream pathways including, e.g., mTOR, FOXO3, etc.61. Literature data 
are very limited on the cardiac expression of AMPK in CKD. Yang et al. reported that a uremic toxin indoxyl 
sulfate induced hypertrophy by inhibiting the AMPK/uncoupling protein 2 signaling pathway in neonatal rat 
cardiomyocytes62. However, there is no data available on cardiac AMPK expression at the protein level in animal 
studies in CKD.
The development of the HFpEF in CKD seems to be unique and distinct from other types of cardiac hyper-
trophies, such as the commonly studied compensatory hypertrophy and subsequent heart failure type induced 
by pressure-overload. In CKD, distinct mechanisms, e.g., unique CKD-associated factors, compensatory hyper-
trophy, pathologic remodeling, cell death, and survival mechanisms could be activated simultaneously. The 
Gene name Gene symbol log2 change SD log2 change p-value Fold change
Natriuretic peptide A (ANP) Nppa 1.80 1.88 0.000 3.48*
Natriuretic peptide B (BNP) Nppb −0.55 1.63 0.118 −1.46
Myosin, Heavy Polypeptide 6, Cardiac Muscle, Alpha (α-MHC) Myh6 −1.26 1.34 0.000 −2.39*
Myosin, Heavy Polypeptide 7, Cardiac Muscle, Beta (β-MHC) Myh7 −0.71 1.06 0.000 −1.64
Myocyte enhancer factor 2 C (predicted) Mef2c 0.23 0.25 0.000 1.17
Myocyte enhancer factor 2D Mef2d 0.05 0.21 0.201 1.03
Table 4. The effect of CKD on the molecular markers of left ventricular hypertrophy and fibrosis. Gene 
expression ratios (CKD vs. control). Fold change of <−1.75 or >1.75 (repression or overexpression, 
respectively) and a p-value of <0.05 were considered as a significant change*, n = 6, unpaired t-test or Mann 
Whitney U test (Nppa, Nppb, and Mef2c).
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individual pathways may converge toward key down-stream regulators (e.g., FOXO3, AKT, ERK1/2, AMPK, 
mTOR, etc.) and the ensuing effects may cancel each other, as reflected in unchanged protein levels.
In summary, this is the first study to report that LVH and fibrosis in CKD are accompanied by characteris-
tic miR-212 overexpression in the left ventricle. However, it needs to be further explored whether the cardiac 
Figure 5. qRT-PCR and Western blot results at week 9. Left ventricular (a) miR-212 expression, (b) total AKT 
expression, (c) phospho-AKT expression, (d) phospho-AKT/total AKT ratio, (e) FOXO3 mRNA expression, (f) 
total FOXO3 expression, (g) phospho-FOXO3 expression, and (h) phospho-FOXO3/total FOXO3 ratio. White 
bars represent the sham-operated group, and grey bars represent the chronic kidney disease (CKD) group. 
Values are means ± SEM, n = 7–8, *p < 0.05, unpaired t-test (a–e) or Mann-Whitney-U test (f–h).
Figure 6. mTOR Western blot results at week 9. Left ventricular (a) total mTOR expression, (b) phospho-
mTOR expression, and (c) phospho-mTOR/total mTOR ratio. White bars represent the sham-operated group, 
and grey bars represent the chronic kidney disease (CKD) group. Values are means ± SEM, n = 7–8, *p < 0.05, 
unpaired t-test.
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overexpression of miR-212 is a cause or consequence of LVH in CKD. The molecular mechanism of the devel-
opment of LVH and fibrosis in CKD seems to be distinct from other forms of hypertrophy and pathological 
remodeling.
Limitations
Our results regarding altered cardiac gene expression due to CKD are based on selected miRs and target mole-
cules, however, measurement of the full rat transcriptome should be performed in the future. In this study, the 
focus was on miR-212 with its selected hypertrophy-associated target molecules, the relative role of other miRs 
or other miR-212 targets were not assessed in the development of cardiac hypertrophy in CKD. This study is 
descriptive; therefore future studies providing more in-depth mechanistic insight are necessary. Moreover, this is 
an exploratory study, thus therapeutic intervention was out of the scope.
Materials and Methods
This investigation conformed to the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals (NIH Publication No. 85-23, Revised 1996) and was approved by the Animal Research Ethics Committee 
of Csongrád County (XV.1181/2013) and the University of Szeged (MÁB-I-74-2017) in Hungary. All institutional 
and national guidelines for the care and use of laboratory animals were followed.
Animals. A total of 66 adult male Wistar rats (250–300 g) were used in this study. 30 animals underwent 
sham-operation, and 36 animals received 5/6 nephrectomy to induce CKD. Animals were housed in pairs in indi-
vidually ventilated cages (Sealsafe IVC system, Italy) and were maintained in a temperature-controlled room with 
a 12-h:12-h light/dark cycles throughout the study. Standard rat chow and tap water were supplied ad libitum.
experimental setup. Experimental CKD was induced by 5/6 nephrectomy. Animals underwent a sham 
operation or 5/6 nephrectomy in two phases as we described previously63 (Fig. 1). After the operations, both 
groups were followed-up for 9 weeks. At week −1, 4 and 8, cardiac morphology and function were assessed by 
transthoracic echocardiography in a subgroup of both the 5/6 nephrectomized and sham-operated rats (n = 10) 
(Fig. 1). At week −1, and 4, blood was collected from vena saphena (n = 10), and at week 9 from the thoracic aorta 
(n = 9–10), and serum urea and creatinine levels were measured. Serum ion levels were determined only at week 
9. Moreover, this subgroup of animals was placed in metabolic cages at week −1, 4 and 8 for 24 h to measure urine 
creatinine and protein levels (Fig. 1). At week 8, oral glucose tolerance test (OGTT), blood glucose, and plasma 
insulin measurement were also performed in another subgroup of animals (n = 9–10). In a separated subgroup 
of animals, invasive blood pressure measurements were performed in the right carotid artery at week 8 (Fig. 1) 
(n = 10–13). At the termination of the experiment at week 9, rats were anesthetized, and hearts were isolated and 
perfused according to Langendorff, then left ventricles were separated, and samples were prepared for histology 
and biochemical measurement. The development of LVH and fibrosis in CKD was verified by the measurement 
of myocardial fibre diameters as well as picrosirius red staining for collagen. Total RNA was isolated from the left 
ventricles, and the myocardial expression of miR-212 and its selected mRNA targets were measured by qRT-PCR. 
Moreover, left ventricular expression of total-FOXO3, phospho-FOXO3, total-AKT, phospho-AKT, total-mTOR, 
Gene name Gene symbol log2 change SD log2 change p-value Fold change
Protein phosphatase 3 catalytic subunit alpha Ppp3ca 0.14 0.21 0.000 1.10
Protein phosphatase 3 catalytic subunit beta Ppp3cb 0.01 0.38 0.896 1.01
Nuclear Factor Of Activated T-Cells, Cytoplasmic, Calcineurin-
Dependent 4 Nfatc4 −0.05 0.97 0.775 −1.03
Muscle Atrophy F-Box Protein (atrogin-1) Fbx32 −0.92 1.21 0.001 −1.89
Myocyte-Enriched Calcineurin-Interacting Protein 1 (MCIP1.4) Rcan1 −0.12 1.81 0.781 −1.09
Table 5. The effect of CKD on molecular markers of the calcineurin/NFAT pathway at the mRNA level. 
Gene expression ratios (CKD vs. control). Fold change of <−1.75 or >1.75 (repression or overexpression, 
respectively) and a p-value of <0.05 were considered as a significant change, n = 5–6, unpaired t-test.
Gene name Gene symbol log2 change SD log2 change p-value Fold change
Mitogen activated protein kinase 1 (ERK2) Mapk1 −0.22 0.24 0.000 −1.17
Myocyte enhancer factor 2a Mef2a −0.11 0.29 0.026 −1.08
Protein kinase AMP-activated catalytic subunit alpha 2 (AMPK) Prkaa2 −0.22 0.34 0.000 −1.16
DnaJ heat shock protein family (HSP40) member A2 Dnaja2 −0.18 0.18 0.002 0.88
Sirtuin 1, transcript variant X1 (predicted) Sirt1 −0.02 0.34 0.750 −1.01
Phosphatase and tensin homolog Pten 0.13 0.25 0.003 1.10
Table 6. The effect of CKD on hypertrophy-associated selected targets of miR-212. Gene expression ratios 
(CKD vs. control). Fold change of <−1.75 or >1.75 (repression or overexpression, respectively) and a p-value 
of <0.05 were considered as a significant change*, n = 5–6, unpaired t-test or Mann Whitney U test (Dnaja2).
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phospho-mTOR, total-ERK1, total-ERK2, phospho-ERK1, phospho-ERK2, total-AMPK, and phospho-AMPK 
were measured by Western blot technique.
5/6 nephrectomy. Sham operation and 5/6 nephrectomy were performed in two phases as described pre-
viously63. Anesthesia was induced by intraperitoneal injection of pentobarbital sodium (Euthasol; 40 mg/kg; 
Produlab Pharma b.v., Raamsdonksveer, The Netherlands). At the first operation, two pieces of sutures (5–0 
Mersilk; Ethicon, Sommerville, NJ) were placed around both poles of the left kidney approximately at the 1/3 
position. Then the sutures were gently ligated around the kidney. The 1/3 kidney on both ends was excised right 
beyond the ligatures. Accidental bleeding was alleviated by thermal cauterization. One week after the first oper-
ation, animals were anesthetized, and the right kidney was freed from the surrounding adipose tissue as well as 
Figure 7. ERK1/2 and AMPK Western blot results at week 9. Left ventricular (a) total ERK1 and ERK2 
expressions, (b) phospho-ERK1 and phospho-ERK2 expressions, (c) phospho-ERK1/total ERK1 and phospho-
ERK2/total ERK2 ratios, (d) total AMPK expression, (e) phospho-AMPK expression, and (f) phospho-AMPK/
total AMPK ratio. White bars represent the sham-operated group, and grey bars represent the chronic kidney 
disease (CKD) group. Values are means ± SEM, n = 7–8, *p < 0.05, unpaired t-test.
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the renal capsule, and then it was pulled out of the incision gently. The adrenal gland was gently freed and was 
placed back into the abdominal cavity. The renal blood vessels and the ureter were ligated, and the right kidney 
was removed. During sham operations, renal capsules were removed. After the surgeries, the incision was closed 
with running sutures, and povidone iodide was applied on the surface of the skin. As a post-operative medication, 
0.3 mg/kg nalbuphine hydrochloride (Nalbuphine 10 mg/ml; TEVA, Debrecen, Hungary) was administered sub-
cutaneously. Antibiotics (Enroxil, 75 mg; Krka, Slovenia) and analgesics (10 mg/L of nalbuphine hydrochloride, 
Nalbuphine; TEVA) were administered in tap water for 2 days after both surgeries.
transthoracic echocardiography. Cardiac morphology and function were assessed by transthoracic 
echocardiography at week −1, 4, and 8 (Fig. 1). Rats were anesthetized with 2% isoflurane (Forane, AESICA, 
Queenborough Limited Kent, UK). Then, the chest was shaved, and the rat was placed in a supine position onto a 
heating pad. Two-dimensional, M-mode, Doppler, and tissue Doppler echocardiographic examinations were per-
formed by the criteria of the American Society of Echocardiography with a Vivid 7 Dimension ultrasound system 
(General Electric Medical Systems) using a phased array 5.5–12 MHz transducer (10S probe) as described previ-
ously63–65. Data of three consecutive heart cycles were analysed (EchoPac Dimension software; General Electric 
Medical Systems) by an experienced investigator in a blinded manner. The mean values of three measurements 
were calculated and used for statistical evaluation.
Blood pressure measurement. To measure arterial blood pressure, a 1.6 F, polyamide, pressure catheter 
(Scisense Systems Inc, London, ON, Canada) was inserted into the right carotid artery at week 8 under anesthesia 
(Euthasol; 40 mg/kg; Produlab Pharma b.v., Raamsdonksveer, The Netherlands) in a separated subgroup of ani-
mals as we described previously66. Blood pressure measurements were performed between 09:00 and 14:00 hours.
Urine creatinine and total protein levels. At week −1, 4 and 8, a subgroup of animals was placed in 
metabolic cages (Tecniplast, Italy) for 24 h to collect urine for the measurement of urine creatinine and protein 
levels to verify the development of CKD. Urine creatinine and urine protein levels were measured by standard 
laboratory methods as described previously63.
serum carbamide and creatinine levels. Blood was collected in a subgroup of animals from the saphen-
ous vein at week −1 and 4 and from the thoracic aorta at week 9 to measure serum carbamide (urea) and creati-
nine levels to verify the development of CKD. Urea and creatinine levels in serum were quantified by kinetic UV 
method using urease and glutamate dehydrogenase enzymes and Jaffe method, respectively. The reagents and the 
platform analysers were from Roche Diagnostics (Mannheim, Germany)63.
Creatinine clearance. Creatinine clearance, an indicator of renal function, was calculated according to the 
standard formula (urine creatinine concentration [μM] × urine volume for 24 h [mL])/(serum creatinine con-
centration [μM] × 24 × 60 min)63. Urine volume and urine creatinine concentration were measured at week 8 and 
serum creatinine concentration was determined at week 9.
serum ion levels. Serum sodium, potassium, calcium, magnesium, phosphate and chloride levels were 
determined by indirect potentiometry using ion-selective electrodes at week 9. All reagents and instruments were 
from Roche Diagnostics (Mannheim, Germany)63.
Blood glucose level and oGtt. As described previously, a subgroup of rats was fasted overnight (12h) 
before blood glucose level measurements to check the development of hyperglycaemia and glucose-intolerance in 
CKD at week 867–70. Blood samples were collected from the saphenous vein. Blood glucose levels were measured 
using AccuCheck blood glucose monitoring systems (Roche Diagnostics Corporation, USA, Indianapolis)67–70. 
In case of OGTT, after the measurement of baseline glucose concentrations, 1.5 g/kg body weight glucose was 
administered per os via gavage, and blood glucose levels were checked 30, 60 and 120 min later67–70.
plasma insulin levels. Plasma insulin levels were measured by an enzyme-linked immunosorbent assay 
(Mercodia, Ultrasensitive Rat Insulin ELISA) as described previously67–70. Blood samples were collected from the 
saphenous vein at week 8. Insulin ELISA was carried out according to the instructions of the manufacturer from 
the plasma.
Ex vivo cardiac perfusions and tissue harvesting. Hearts isolated from the animals were perfused for 
5 minutes with oxygenated Krebs-Henseleit solution according to Langendorff as described previously67,69–71. 
Coronary flow was measured at the 5th minute. Then the hearts were weighed, left and right ventricles were sepa-
rated, and a cross-section of the left ventricle at the ring of the papillae was cut and fixed in 10% buffered formalin 
for histological analysis. Other parts of the left ventricles were freshly frozen and stored at −80 °C until further 
biochemical measurements. Body and kidney weights were also measured.
Hematoxylin-eosin staining. Five-μm paraffin-embedded transverse cut sections of the formalin-fixed 
subvalvular area of the ventricles were stained with hematoxylin-eosin. On these slides, myocardial fibre diam-
eters were measured to verify the development of LVH as described by others72. Transverse transnuclear widths 
(cardiomyocyte diameter) were measured in 100 longitudinally oriented, mono-nucleated cardiomyocytes on left 
ventricular sections cut on the same plane72.
picrosirius red staining and image analysis. Five-μm paraffin-embedded transverse cut sections of the 
formalin-fixed subvalvular area of the ventricles were stained with picrosirius red to assess cardiac fibrosis as 
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described previously65. Histological slides were scanned with a Pannoramic P250 scanner (3D-Histech, Budapest, 
Hungary) and digital images at the magnification of ×20, ×40 and ×100 were captured. Medium-size vessels and 
their perivascular connective tissue sheet, the subepicardial and subendocardial areas were avoided as best as 
possible. The picrosirius red dyed images were analyzed with an in-house developed program as described previ-
ously65. This program determines the proportion of red pixels of heart sections using two simple color filters. For 
each Red-Green-Blue (RGB) pixel, the program calculates the color of the pixel in Hue-Saturation-Luminance 
(HSL) colour space. The first filter is used for detecting red portions of the image. The second filter excludes any 
white (empty) or light grey (residual dirt on the slide) pixel from further processing using a simple RGB thresh-
old. In this way, the program groups each pixel into one of two sets: pixels considered red and pixels considered 
green but neither red, nor white, nor grey. Red pixels in the first set correspond to connective tissue and fibrosis. 
Green pixels in the second set correspond to cardiac muscle. Dividing the number of elements in the first set by 
the number of elements in both sets gives the proportion of the connective tissue compartment of the heart area 
examined.
MicroRNA expression profiling by qRT-PCR. Quantitative RT-PCR was performed with miR-specific 
primers to monitor miR expression as described earlier23. In the case of miRs, RNA was isolated from left ventri-
cles using Trizol reagent (Invitrogen, #15596-018). For quantitative detection of miR-212, TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems, #4366597), TaqMan miRNA-212 and snoRNA (U64702) Assays 
(Applied Biosystems, #A25576 and #4427975) and Absolute Blue qPCR Mix (Abgene, #AB-4136/B) were used 
according to the manufacturer’s instructions. SnoRNA U64702 was used as a control for normalization.
mRNA expression profiling by qRT-PCR. Quantitative RT-PCR was performed with gene-specific prim-
ers to monitor mRNA expression as described previously67 (Supplementary Table 1). Target mRNAs of miR-212 
associated with cardiac hypertrophy and heart failure were selected in the TargetScan database (Table 6). RNA 
was isolated using Qiagen RNeasy Fibrous Tissue Mini Kit (Qiagen, #74704) from heart tissue. Briefly, 3 µg of 
total RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
#4368814), specific primers and FastStart Essential DNA Green Master (Roche, #06402712001) were used 
according to the manufacturer’s instructions. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh), hypoxan-
thine phosphoribosyl transferase 1 (Hprt1), peptidyl prolyl isomerase A (Ppia), and ribosomal protein lateral 
stalk subunit P2 (Rplp2) were used as controls for normalization.
Matrix metalloprotease 2 (MMP-2) zymography. Cardiac MMP-2 activity was measured from homog-
enized left ventricular samples to estimate the collagen breakdown in the cardiac extracellular matrix as described 
previously73,74. Briefly, polyacrylamide gels were copolymerized with gelatine, and 40 μg protein was separated 
by electrophoresis (150 V, 1.5 h) in each lane. Following electrophoresis, gels were washed with 2.5% Triton 
X-100 and incubated for 20 hours at 37 °C in incubation buffer. Gels were then stained with 0.05% Coomassie 
Brilliant Blue in a mixture of methanol/acetic acid/water and destained in aqueous 4% methanol/8% acetic acid. 
Zymograms were digitally scanned, and band intensities were quantified using Quantity One software (Bio-Rad, 
Hercules, CA).
Western blot. To investigate gene expression changes at the protein level, standard Western blot technique 
was used in case of phospho-AKT, AKT, phospho-ERK1/2, ERK1/2, phospho-FOXO3, FOXO3, phospho-AMPK, 
AMPK, mTOR, and phospho-mTOR with GAPDH loading background23,75,76 (Supplementary Figs 1–14). Heart 
tissue samples (n = 7–8) were homogenized with an ultrasonicator (UP100H Hielscher, Teltow, Germany) in 
Radio Immunoprecipitation Assay (RIPA) buffer (50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 0.5% sodium deoxy-
cholate, 5 mM ethylenediamine tetra-acetic acid (EDTA), 0.1% sodium dodecyl sulfate, 1% NP-40 (Cell Signaling, 
Carlsbad, CA, USA) supplemented with protease inhibitor cocktail and phosphatase inhibitors phenylmethane 
sulfonyl fluoride (PMSF) and sodium fluoride (NaF, Sigma, Saint Louis, MO, USA). The crude homogenates were 
centrifuged at 15000 × g for 30 min at 4 °C. After quantification of protein concentrations of the supernatants 
using BCA Protein Assay Kit (Pierce, Rockford, IL, USA), 25 μg of reduced and denaturated protein was loaded. 
Then sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was performed (10% gel, 90 V, 
2 h in case of AKT, ERK1/2, FOXO3, and AMPK, and 6% gel, 50 V, 5 h in case of mTOR) which was followed by 
transfer of proteins onto a nitrocellulose membrane (20% methanol, 35 V, 2 h in case of AKT, ERK1/2, FOXO3, 
and AMPK and 10% methanol, 20 V, 16 h, 4 °C in case of mTOR). The efficacy of transfer was checked using 
Ponceau staining. The membranes were cut horizontally into parts corresponding to the molecular weights of 
AKT, ERK1/2, FOXO3, AMPK, mTOR and GAPDH and were blocked for 1 h in 5% (w/v) bovine serum albumin 
(BSA) or milk at room temperature and then incubated with primary antibodies in the concentrations of 1:1000 
against phospho-AKT (Ser473, #4060), AKT (#9272), phospho-ERK1/2 (Thr202/Tyr204, #9101 S), ERK1/2 
(#9102), phospho-FOXO3 (Ser253; #13129), phospho-AMPK (Thr172; #2535), AMPK (#5831), mTOR (#2972), 
phospho-mTOR (Ser2448, #2971, overnight, 4 °C, 5% BSA), 1:500 against FOXO3 (#2497, overnight, 4 °C, 5% 
BSA) and 1:5000 against GAPDH (#2118 overnight, 4 °C, 1% BSA).
Then the membranes were incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit sec-
ondary antibody 1:2000 (1:1000 for FOXO3, 1:5000 for GAPDH) (Dako Corporation, Santa Barbara, CA, USA; 
45 min, room temperature, 1% BSA). After assessment of phosphorylated proteins, the membranes were stripped 
and reassessed for the total amount of proteins. An enhanced chemiluminescence kit (Cell Signaling, Carlsbad, 
CA, USA) was used to develop the membranes. The chemiluminescence signals were analyzed and evaluated by 
Quantity One Software.
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statistical analysis. The sample size was calculated using the Power and Sample Size Calculation 3.0 free 
software. Statistical analysis was performed using Sigmaplot 12.0 for Windows (Systat Software Inc). All values 
are presented as mean ± SEM. Data showed normal distribution unless otherwise indicated. Baseline and differ-
ent follow-up data including serum metabolite and ion concentrations, and echocardiographic data were com-
pared using Repeated Measures Two-Way ANOVA among the sham and CKD groups. Holm-Sidak test was used 
as post hoc test. Two sample t-test (in case of normal distribution of the data) or Mann Whitney U test (in case 
of non-normal distribution of the data) were used to determine the effect of CKD on all measured parameters 
within each time point. P < 0.05 was accepted as a statistically significant difference. In the case of target genes, 
the analysis of relative gene expression data was performed using the 2−ΔΔCt method. Gene expression ratios with 
a p-value of <0.05 and fold change of <−1.75 or fold change of >1.75 were considered as repression or overex-
pression respectively in gene activity.
Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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